Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

Launched by LEO PHARMA · Dec 8, 2005

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Psoriasis vulgaris involving trunk and/or arms and/or legs amenable to treatment with a maximum of 100 g of topical medication per week
• • An investigators' global assessment of disease severity of at least mild
• Exclusion Criteria:
• • PUVA or Grenz ray therapy within 4 weeks prior to randomisation
• • UVB therapy within 2 weeks prior to randomisation
• • Systemic treatment with biological therapies, with a possible effect on psoriasis vulgaris within 6 months prior to randomisation
• • Systemic treatment with all other therapies than biologicals, with a possible effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids, immunosuppressants) within 4 weeks prior to randomisation
• • Any topical treatment of the trunk/limbs (except for emollients) within 2 weeks prior to randomisation
• • Topical treatment for other relevant skin disorders (except WHO group I-II corticosteroids, tar, retinoid and dithranol on face, scalp, or flexures) within 2 weeks prior to randomisation
• • Planned initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium) during the study
• • Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis